Oscar Health, Inc. (NYSE:OSCR – Get Free Report) insider Mario Schlosser sold 6,516 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $18.08, for a total value of $117,809.28. Following the completion of the sale, the insider now owns 81,962 shares in the company, valued at $1,481,872.96. This trade represents a 7.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Oscar Health Trading Down 5.7 %
NYSE OSCR opened at $16.96 on Thursday. The firm has a market cap of $4.19 billion, a P/E ratio of -282.62 and a beta of 1.63. The company has a debt-to-equity ratio of 0.26, a current ratio of 0.73 and a quick ratio of 0.73. The stock’s 50-day moving average is $17.18 and its 200-day moving average is $17.94. Oscar Health, Inc. has a one year low of $7.50 and a one year high of $23.79.
Oscar Health (NYSE:OSCR – Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.02). The company had revenue of $2.42 billion during the quarter, compared to the consensus estimate of $2.33 billion. Oscar Health had a net margin of 0.35% and a return on equity of 2.79%. The firm’s revenue for the quarter was up 68.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.29) earnings per share. Sell-side analysts anticipate that Oscar Health, Inc. will post -0.01 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Oscar Health
Wall Street Analyst Weigh In
A number of brokerages have weighed in on OSCR. Bank of America cut Oscar Health from a “neutral” rating to an “underperform” rating and lowered their price target for the company from $21.00 to $13.50 in a research report on Wednesday, November 6th. UBS Group assumed coverage on Oscar Health in a research report on Monday, October 7th. They issued a “neutral” rating and a $23.00 price target on the stock. Finally, Piper Sandler reiterated an “overweight” rating and issued a $28.00 price target on shares of Oscar Health in a report on Tuesday, September 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $22.93.
View Our Latest Stock Analysis on OSCR
Oscar Health Company Profile
Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.
Featured Stories
- Five stocks we like better than Oscar Health
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Tesla Poised to Hit Record Highs This Holiday Season
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- The Salesforce Rally is Just Getting Started: Here’s Why
- Overbought Stocks Explained: Should You Trade Them?
- 3 Chip and Data Center Stocks That Can Keep Rising in 2025
Receive News & Ratings for Oscar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oscar Health and related companies with MarketBeat.com's FREE daily email newsletter.